Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
Portfolio Pulse from Benzinga Insights
In the last three months, 11 analysts have published ratings on Ultragenyx Pharmaceutical (NASDAQ:RARE), showing a range of perspectives from bullish to bearish. The average 12-month price target is $81.36, with a high of $127.00 and a low of $47.00. Recent analyst actions include both raises and lowers in ratings and price targets. Ultragenyx has shown an 8.3% revenue growth rate but faces challenges with a net margin of -156.83%, ROE of -82.12%, and ROA of -12.2%. The company's debt-to-equity ratio is 0.29, indicating less reliance on debt financing.
May 31, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical (NASDAQ:RARE) has received mixed analyst ratings over the past three months, with an average price target of $81.36. The company has shown positive revenue growth but faces significant challenges with its net margin, ROE, and ROA. The debt-to-equity ratio is favorable, indicating less reliance on debt.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on the stock price. Positive revenue growth is offset by significant challenges in net margin, ROE, and ROA. The favorable debt-to-equity ratio is a positive factor but not enough to drive a significant price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100